IP Library › Granted Patent US 11,077,044
Granted Patent B2
US 11,077,044 · App. 16/071,658 · Granted Aug 3, 2021

Compositions that brighten skin, provide sun protection, and permit vitamin D production

Inventor: Ernest T. Armstrong (Palm Desert, CA)
A61K8/4946A61K8/345A61K8/347A61K8/35A61K8/37A61K8/42A61K8/44A61K8/466A61K8/4926A61K8/60A61K8/675A61K8/676A61Q17/04A61Q19/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,077,044
App. No.
16/071,658
Granted
Aug 3, 2021
Kind
B2
Abstract

The present invention relates to sunscreen compositions. More specifically, the present invention relates to sunscreen compositions that, when applied to the skin, prevent sun damage while allowing the passage of sufficient UVB in the range of 290 nm-298 nm to produce vitamin D, while also inhibiting melanogenesis.

Claims (23)

1. A topical sunscreen composition to prevent facultative pigmentation and protect skin from sun damage while permitting the skin to produce vitamin D, the composition comprising:

a combination of UVR filtering agents to selectively filter enough light in UVA and UVB ranges to prevent UVR-induced skin damage while permitting passage of at least 5% of UVB in a range of approximately 290 nm-298 nm to permit vitamin D production, wherein the combination of the UVR filtering agents includes:

octocrylene at a concentration of about 0.5% to about 10% (w/w),

butyl methoxy dibenzoylmethane at a concentration of about 0.5% to about 7% (w/w),

homosalate at a concentration of about 0.5% to about 15% (w/w), and

octyl salicylate at a concentration of about 0.5% to about 10% (w/w); and

a combination of melanogenesis inhibition compounds to inhibit melanogenesis and the corresponding facultative pigmentation of the skin even though the skin absorbs the at least 5% of UVB in the range of approximately 290 nm-298 nm, wherein the combination of the melanogenesis inhibition compounds includes:

1-methylhydantoin-2-imide at a concentration of about 0.05% to about 5% (w/w),

niacinamide at a concentration of about 0.5% to about 10% (w/w), and

phenylethyl resorcinol at a concentration of about 0.05% to about 7% (w/w),

wherein absorption of the UVB in the range of approximately 290 nm-298 nm by the skin typically results in production of melanin by the skin and the corresponding facultative pigmentation of the skin in addition to vitamin D production,

wherein the combination of the melanogenesis inhibition compounds do not effectively filter UVB in the range of approximately 290 nm-298 nm, and

wherein the composition does not include any compounds or components at concentrations that would effectively filter UVB in the range of approximately 290 nm-298 nm.

2. The topical sunscreen composition of claim 1 , wherein the combination of the UVR filtering agents permit passage of at least 10% of the UVB light in the range of approximately 290 nm-298 nm.

3. The topical sunscreen composition of claim 1 , wherein the combination of the UVR filtering agents include octyl salicylate at a concentration of about 2.3% (w/w).

4. The topical sunscreen composition of claim 1 , wherein the combination of the UVR filtering agents include butyl methoxy dibenzoylmethane at a concentration of approximately 3% (w/w).

5. The topical sunscreen composition of claim 1 , wherein the combination of the UVR filtering agents include homosalate at a concentration of approximately 4.9% (w/w).

6. The topical sunscreen composition of claim 1 , wherein the combination of the UVR filtering agents include octocrylene at a concentration of about 2.7% (w/w).

7. The topical sunscreen composition of claim 1 , wherein the combination of the melanogenesis inhibition compounds include phenylethyl resorcinol at a concentration of approximately 1.0% (w/w).

8. The topical sunscreen composition of claim 1 , wherein the combination of the melanogenesis inhibition compounds include 1-methylhydantoin-2-imide at a concentration of approximately 1.5% (w/w).

9. The topical sunscreen composition of claim 1 , wherein the combination of the melanogenesis inhibition compounds include niacinamide at a concentration of approximately 3.0% (w/w).

10. The topical sunscreen composition of claim 1 , further comprising glycerin at a concentration of between 0.25% and 8% (w/w).

11. The topical sunscreen composition of claim 1 , further comprising panthenol at a concentration of between 0.25% and 10% (w/w).

Priority Claims (1)
AU 2016900200 · Jan 22, 2016 · national
Continuity (1)
Related Publication 20190076346A1 · Mar 14, 2019
Cited By (1)
US 12,427,080